Randomized Phase II Study Evaluating Palbociclib in Addition to ...

PALLET is a phase II randomized trial that evaluated the effects of combination palbociclib plus letrozole as neoadjuvant therapy.

PALLET Trial - PubMed

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast ...

CDK4/6 inhibitors are used to treat estrogen receptor (ER)-positive metastatic breast cancer (BC) in combination with endocrine therapy. PALLET is a phase ...

Randomized Phase II Study Evaluating Palbociclib in Addition to ...

... Trials. Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer ...

A Phase II Randomized Study Evaluating the Biological and Clinical ...

... trial of letrozole (L) palbociclib (P). open_in_new. J Clin Oncol 2018 - Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as ...

[PDF] Randomized Phase II Study Evaluating Palbociclib in Addition ...

Adding palbociclib to letrozole significantly enhanced the suppression of malignant cell proliferation (Ki-67) in primary ER-positive BC, ...

(PDF) Randomized Phase II Study Evaluating Palbociclib in Addition ...

PALLET is a phase II randomized trial that evaluated the effects of combination palbociclib plus letrozole as neoadjuvant therapy. ... Palbociclib 125 mg/d was ...

Palbociclib and Letrozole in Advanced Breast Cancer

... randomised phase 2 study. Lancet Oncol 2015;16:25-35. Crossref ... Phase III trial evaluating the addition of bevacizumab to endocrine ...

Randomized Phase II Study Evaluating Palbociclib in Addition to ...

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial.

A phase II study of palbociclib plus letrozole plus trastuzumab as ...

For example, NeoPalAna evaluated neoadjuvant palbociclib plus anastrozole for early ER+/HER2- breast cancer and showed that the addition of ...

Randomized Phase II Study Evaluating Palbociclib in ... - Altmetric

Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial.

A Randomized Phase II Study of Androgen Deprivation Therapy with ...

We hypothesized that co-targeting AR and cell-cycle with palbociclib would improve outcomes in patients with metastatic hormone sensitive prostate cancer (mHSPC) ...

Randomized phase II study of fulvestrant plus palbociclib or placebo ...

The potential benefit of adding palbociclib to fulvestrant as first-line treatment in hormone receptor (HR)-positive, human epidermal growth factor receptor ...

Palbociclib with adjuvant endocrine therapy in early breast cancer ...

29. Johnston, S ∙ Puhalla, S ∙ Wheatley, D ∙ et al. Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant ...

Palbociclib and Trastuzumab in HER2-Positive Advanced Breast ...

The phase III PATINA trial (36) is testing the value of adding palbociclib ... randomised, open-label, phase 2 trial . Lancet Oncol. 2020. ;. 21. : 763. –. 75.

Clinical Trials Using Palbociclib - NCI

A randomized, Phase II trial of circulating tumor DNA-guided second line ... This is a Phase 3, open-label, randomized, clinical trial evaluating the ...

PALLET Supplementary Material A randomized phase II study ...

A randomized phase II study evaluating palbociclib in addition to letrozole as neo- adjuvant therapy in estrogen-receptor positive early breast cancer ...

a phase III randomised controlled trial—PEARL - Annals of Oncology

Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase ...

Neoadjuvant palbociclib plus either giredestrant or anastrozole in ...

Johnston, S ∙ Puhalla, S ∙ Wheatley, D ∙ et al. Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant ...

Efficacy and safety of palbociclib in combination with letrozole as ...

In the randomized, open-label, phase II PALOMA-1/TRIO-18 trial, palbociclib in combination with letrozole improved progression-free survival ( ...